Government-Owned Inventions; Availability for Licensing, 4610 [2024-01364]
Download as PDF
<![CDATA[
4610
Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Patient-Oriented Research Study
Section.
Date: February 29–March 1, 2024.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Fungai Chanetsa, Ph.D.,
MPH, Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 206–
B, Bethesda, MD 20817, (301) 402–9394,
fungai.chanetsa@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: January 18, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–01296 Filed 1–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Ben
Hurley at 240–669–5092, or
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:06 Jan 23, 2024
Jkt 262001
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Hybridoma Cell Lines 2A4 and 5B12
Against Puromycin Description of
Technology
Protein translation is a central cellular
function attracting increasing attention
from cell biologists as they integrate
gene product specific information into a
systems view of cellular function.
Scientists at NIAID developed the
puromycin-specific antibodies that
allow for the specific detection of
puromycin-containing nascent
polypeptides via standard
immunofluorescence or flow cytometry.
The resulting ribopuromycylation
method (RPM) localizes translation in
cells and can be applied to any PMYsensitive eukaryotic or prokaryotic cell
to study the dynamics of protein
synthesis at the cellular level and
investigate translational processes. It
can also be used in vitro or in vivo to
measure the number of translating
ribosomes using flow cytometry.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Broad application for studying protein
translation.
Competitive Advantages:
• This technology generates antibodies
specific for puromycin that can be
used to localize translating ribosomes
in all cell types.
Development Stage:
• Research Materials
Inventors: Jonathan Yewdell, MD,
Ph.D., Alexandre David, Ph.D., both of
NIAID.
Publications: David A. Dolan BP,
Hickman HD, Knowlton JJ, Clavarino G,
Pierre P, Bennink JR, Yewdell JW.
Nuclear translation visualized by
ribosome-bound nascent chain
puromycylation. J Cell Biol. 2012 Apr
2;197(1):45–57. doi: 10.1083/
jcb.201112145. PMID: 22472439;
PMCID: PMC3317795.
Also: PMID 29552591, 27385780,
25311127, 23229864.
Intellectual Property: HHS Reference
No. E–003–2021.
Licensing Contact: To license this
technology, please contact Ben Hurley
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
at 240–669–5092, or benjamin.hurley@
nih.gov, and reference E–003–2021.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Ben Hurley at 240–669–5092, or
benjamin.hurley@nih.gov.
Dated: January 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–01364 Filed 1–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Biobehavioral Processes.
Date: February 15, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jeanne M. McCaffery,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–594–3854, jeanne.mccaffery@
nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Chemical Biology and Probes
Study Section.
Date: February 15–16, 2024.
Time: 10:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\24JAN1.SGM
24JAN1
]]>Agencies
[Federal Register Volume 89, Number 16 (Wednesday, January 24, 2024)]
[Notices]
[Page 4610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01364]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Ben Hurley at 240-669-5092, or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION:
Hybridoma Cell Lines 2A4 and 5B12 Against Puromycin Description of
Technology
Protein translation is a central cellular function attracting
increasing attention from cell biologists as they integrate gene
product specific information into a systems view of cellular function.
Scientists at NIAID developed the puromycin-specific antibodies that
allow for the specific detection of puromycin-containing nascent
polypeptides via standard immunofluorescence or flow cytometry. The
resulting ribopuromycylation method (RPM) localizes translation in
cells and can be applied to any PMY-sensitive eukaryotic or prokaryotic
cell to study the dynamics of protein synthesis at the cellular level
and investigate translational processes. It can also be used in vitro
or in vivo to measure the number of translating ribosomes using flow
cytometry.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Broad application for studying protein translation.
Competitive Advantages:
This technology generates antibodies specific for puromycin
that can be used to localize translating ribosomes in all cell types.
Development Stage:
Research Materials
Inventors: Jonathan Yewdell, MD, Ph.D., Alexandre David, Ph.D.,
both of NIAID.
Publications: David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino
G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by
ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr
2;197(1):45-57. doi: 10.1083/jcb.201112145. PMID: 22472439; PMCID:
PMC3317795.
Also: PMID 29552591, 27385780, 25311127, 23229864.
Intellectual Property: HHS Reference No. E-003-2021.
Licensing Contact: To license this technology, please contact Ben
Hurley at 240-669-5092, or [email protected], and reference E-
003-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Ben Hurley at 240-669-5092, or
[email protected].
Dated: January 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-01364 Filed 1-23-24; 8:45 am]
BILLING CODE 4140-01-P
